Biosimilars price point

Prices and savings potential of biosimilars

In principle, biosimilars offer a clear price advantage compared to the respective comparable preparations from the original manufacturers.  Biosimilars are 25 % cheaper when released onto the market than the corresponding biopharmaceutical formerly protected by a patent.  With the increasing spread of biosimilars, savings in the three-digit millions are realistic also in Switzerland.

«With biosimilars, it should be possible to save 100 million francs per year in this country from 2019.»

Rebecca Guntern Flückiger, General Manager of Sandoz Pharmaceuticals AG